The Latest Breaking News from Oncology

Health bodies have called for investment in these ‘essential components of cancer care’ so they do not become ‘optional extras’,

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

If you were to ask most people what causes cancer, the answer would probably be smoking, alcohol, the sun, hair dye or some other avoidable element. But the most important risk factor for cancer is something else: aging. That’s right, the factor most associated with cancer is unavoidable — and…

The US-based biotech company has submitted an application to the Saudi Food and Drug Authority (SFDA) for Breakthrough Medicine Designation, a fast-track regulatory pathway that could make Multikine available to patients as early as this summer.

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

The US-based biotech company has submitted an application to the Saudi Food and Drug Authority (SFDA) for Breakthrough Medicine Designation, a fast-track regulatory pathway that could make Multikine available to patients as early as this summer.

As 19 women are diagnosed with a gynaecological cancer every day, advocates are calling for more funding to improve treatments after decades of underinvestment.

Chloe Hickman is campaigning to make it mandatory to have oncology scans checked by two experts

Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline....